JSJonathan Sive

Jonathan Sive

*This is an algorithmically generated author record based on publicly available information.

Jonathan Sive has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Capturing the Lived Experience of Fatigue Through Integration of Wearable, Environmental, and Patient-Reported Data: A Remote Digital Health Observational Study (Preprint)

    by Derek L Hill, Daniel Powell, Lisa Duncan, Yojana Lotankar, Sandip George, Jeremy Roche, Kate McLeish, Veronica Martinez, Katherine Bradbury, Jonathan Sive, et al.

    BACKGROUND Fatigue is a common, debilitating symptom across many chronic and post-acute conditions, yet it remains difficult to assess in routine care due to its subjective, fluctuating, and context-dependent nature. Conventional fatigue assessments rely primarily on retrospective self-report measures, which lack temporal resolution and ecological validity. Advances in digital health technologies create new opportunities to capture fatigue as it is experienced in daily life through continuous, remote, and patient-centred data collection. OBJECTIVE This study evaluates the feasibility and acceptability of a fully remote digital health platform that integrates wearable sensing, environmental monitoring, cardiorespiratory physiology, and ecological momentary assessment to capture the lived experience of fatigue in everyday life. METHODS The Understanding Patterns of Fatigue in Health and Disease study (NCT05622669) was a fully remote mixed-methods observational study. Participants with long COVID, myeloma, heart failure, and healthy controls completed either 2 or 4 weeks of monitoring. Data were collected using a wrist-worn wearable bracelet, in-home Bluetooth environmental beacons, a chest-worn ECG patch, and a smartphone application delivering ecological momentary assessments of fatigue. Data streams were integrated into unified visual representations combining activity, sleep, location, physiology, and self-reported symptoms. Feasibility was evaluated through recruitment, retention, adherence, and data completeness. Acceptability and interpretability were assessed through end-of-study interviews and optional participant feedback sessions. RESULTS Forty participants were enrolled and 37 completed study monitoring (retention rate 92.5%). Wearable bracelet data were available for 87% of study days, with adherence reaching 93% during periods of device operation. Ecological momentary assessments were completed on 83% of study days, whereas ECG patch data completeness averaged 72%. Twenty-two participants participated in feedback sessions. Participants reported high acceptability of the remote study procedures and considered the integrated visualisations to be plausible representations of their daily routines and symptom experiences. Contextual information derived from room-level location and environmental monitoring improved interpretation of activity and physiological data, enabling identification of behavioural patterns associated with work schedules, treatment cycles, and daily functioning that would not have been apparent from wearable-derived measures alone. CONCLUSIONS A fully remote digital health platform integrating wearable, environmental, physiological, and self-reported data was feasible and acceptable across diverse populations experiencing fatigue. The integration of contextual information with behavioural and physiological monitoring enabled interpretable representations of daily life that participants recognised as meaningful reflections of their lived experience. These findings provide methodological guidance for future digital health studies and support the development of context-aware approaches to fatigue assessment and digital phenotyping in real-world settings. CLINICALTRIAL NCT05622669: Understanding Patterns of Fatigue in Health and Disease study (registered 17 November 2022) INTERNATIONAL REGISTERED REPORT RR2-https://doi.org/10.1136/bmjopen-2023-081416

  • Open Access

    Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma

    by Grace Lau, Cavitha Vivekananthan, Oliver Tomkins, Karimali Keshwani, Suganya Sivabalasingham, Simon Wan, Michael P. Lunn, Shirley D’SA, Jonathan Sive

    Radiotherapy is a definitive treatment for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome with solitary plasmacytoma. However, data on its efficacy and the role of immunochemotherapy are limited. This study evaluated the treatment outcomes of patients with POEMS syndrome receiving radiotherapy as their primary therapy and compared the results of those treated with adjunctive immunochemotherapy with those without. A retrospective analysis of patients with POEMS syndrome referred to the University College London Hospital from 1998 to 2023 was conducted. Among 150 patients with POEMS syndrome, 30 (20%) presented with solitary plasmacytoma. Sixteen patients (53%) received radiotherapy alone, whereas 14 (47%) had combined treatment with radiotherapy and immunochemotherapy, predominantly lenalidomide, and dexamethasone. Treatment responses were greater in the combined treatment group, with clinical, vascular endothelial growth factor, hematological, and radiological responses of 100%, 92%, 100%, and 100%, respectively, compared with 87%, 92%, 85%, and 79% in patients receiving radiotherapy only. The median follow-up for the entire cohort was 124 months, with a 5-year overall survival rate of 100% and a progression-free survival (PFS) rate of 82%. For those receiving radiotherapy alone, the median follow-up was 124 months, with a 3-year PFS rate of 69%. In contrast, no progression was observed among patients treated with combined therapy during the follow-up period (range, 7-54 months). Six patients experienced disease progression, with all having received radiotherapy alone as their first-line treatment. This study demonstrated the high efficacy of radiotherapy in patients with POEMS syndrome and solitary plasmacytoma and highlighted the potential benefits of combining radiotherapy with immunochemotherapy.


  • Open Access

    Real-world evaluation of physiotherapist-led exercise prehabilitation and rehabilitation during autologous stem cell transplantation in myeloma: a single-centre experience

    by Joanne Land, Michael K Luong, Alasdair Longden, Neil Rabin, Charalampia Kyriakou, Jonathan Sive, Abi Fisher, Kwee Yong, Orla McCourt

    Background There is emerging evidence for the role of exercise in optimising function, quality of life (QoL) and reducing hospital length-of-stay if commenced prior to undergoing autologous stem cell transplantation (ASCT). A local pilot study of a prehabilitation and rehabilitation intervention during ASCT for myeloma patients indicated promising results and was adapted to translate into local clinical care. The aim of this report is to describe an overview of a newly implemented physiotherapist-led exercise prehabilitation and rehabilitation service delivered as part of the myeloma ASCT pathway, and present real-world findings related to changes in function and QoL. Methods A service evaluation was conducted at a single-centre tertiary referral hospital for haematopoetic stem cell transplantation in the United Kingdom. A hybrid service using face-to-face clinical assessments and weekly remotely supervised group exercise, via an online video conferencing platform, in the phase between stem cell harvest and admission (prehabilitation), and from discharge to 100 days post-ASCT (rehabilitation). Functional (6 min walk and timed sit-to-stand tests) and patient-reported outcome measures (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-C30) and EuroQol EQ5D-5L were assessed at preharvest, preadmission and in the post-ASCT evaluation (day 100) clinic. Results Patients (n=46) with a diagnosis of multiple myeloma referred for ASCT following induction chemotherapy were assessed. Baseline assessments showed high prevalence of impaired function and lower limb strength. Improvements were evident following prehabilitation prior to admission, which were maintained post-ASCT. Changes in 6 min walk test and timed sit-to-stand were significant and beyond thresholds of clinical importance. Improvements were also seen in the domains of QoL. Conclusions Implementation of physiotherapist-led assessments in the myeloma clinic and group exercise delivery under remote supervision are acceptable to patients undergoing ASCT and indicate benefit in improving function and QoL.


  • Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma

    by S. Asher, R. Shah, S. Ings, J. Horder, F. Newrick, G. Nesr, R. Kesse Adu, M. Streetly, S. Trompeter, L. Lee, et al.


  • Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma

    by Nuno Correia, Emma Dowling, Rakesh Popat, Neil Rabin, Chara Kyriakou, Jonathan Sive, Kwee Yong, Ashutosh Wechalekar


  • Evidence‐based medical treatment of POEMS syndrome

    by Jahanzaib Khwaja, Shirley D'SA, Michael P. Lunn, Jonathan Sive

    Summary: POEMS syndrome is a rare multisystem paraneoplastic disorder due to an underlying low‐level plasma cell dyscrasia. Due to its rarity, there are limited data to guide treatment and there are no consensus guidelines. Therapy choices are dictated by patient characteristics, disease factors and local funding arrangements. The goals of therapy are to eradicate the underlying clone in order to improve quality of life and overall survival. Most evidence has been garnered in the front‐line setting. Localised disease responds well to radiotherapy, whilst for those with systemic disease, the best outcomes are demonstrated with induction chemotherapy followed up with high‐dose melphalan and stem cell rescue if eligible. For transplant‐ineligible patients lenalidomide–dexamethasone remains a preferred treatment option. Data in the relapse setting are scarce. Supportive care including management of neuropathy, endocrinopathy, thrombotic risk and anti‐infective agents is necessary. Future international collaboration is crucial to define optimal treatment strategies particularly in the relapse setting.


  • Open Access

    Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors

    by Wei Yee Chan, Lara Howells, William Wilson, Emilie Sanchez, Louise Ainley, Selina J. Chavda, Emma Dowling, Nuno Correia, Catherine S. Y. Lecat, Annabel McMillan, et al.


  • OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

    by Rakesh Popat, William Wilson, Marquita Camilleri, Ruth De Tute, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, Matthew Streetly, Karthik Ramasamy, et al.


  • Open Access

    Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy

    by Wei Yee Chan, Emilie Sanchez, Selina J. Chavda, Catherine S. Y. Lecat, Louise Ainley, Ke Xu, Brendan Wisniowski, Shameem Mahmood, Xenofon Papanikolaou, Charalampia Kyriakou, et al.


  • Open Access

    Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

    by Jonathan Sive, Kirsty Cuthill, Hannah Hunter, Majid Kazmi, Guy Pratt, Dean Smith, British Society Of Haematology